A Phase I study on the use of another MCL-1 inhibitor, S64315, in MDS and AML is also underway [60].The findings may pave the way for further research into further lines of treatment and therapy for BH3 mimetic-resistant disease. Here, MCL1 is linked to acute myeloid leukemia.